Significant response to oral Etoposide in the treatment of an unresectable cardiac sarcoma. J Pediatr Hematol Oncol 2014 May;36(4):e237-40
Date
05/09/2013Pubmed ID
23652877Pubmed Central ID
PMC4479394DOI
10.1097/MPH.0b013e318290c3b8Scopus ID
2-s2.0-84899905832 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Primary cardiac sarcomas are rare and carry a poor prognosis. The standard of care is complete resection. Outcomes for patients without complete resection are dismal, and the benefit of adjuvant therapy is uncertain. A 9-year-old girl presented with a large right-sided cardiac mass. After biopsy, the tumor was classified as an undifferentiated sarcoma. Resection was not feasible due to apparent invasion of the right ventricle and atrioventricular groove. Treatment with oral etoposide resulted in a 97% reduction in tumor volume and allowed for complete resection of residual tumor. She is alive with no evidence of disease 25 months from diagnosis.
Author List
Collins CL, Bartz PJ, Lal DR, Segura AD, Woods RK, Tower RL 2ndAuthors
Peter J. Bartz MD Chief, Professor in the Pediatrics department at Medical College of WisconsinAnnette D. Segura MD Adjunct Assistant Professor in the Pathology department at Medical College of Wisconsin
Richard L. Tower MD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Administration, OralAntineoplastic Agents, Phytogenic
Biopsy
Child
Etoposide
Female
Heart Neoplasms
Humans
Remission Induction
Sarcoma
